Bevacizumab in the Radiation Treatment of Recurrent Malignant Glioma

NACompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions
Brain CancerRecurrent Malignant GliomasPrimary Brain Tumor
Interventions
OTHER

bevacizumab and radiation (IMRT)

bevacizumab 10 mg/kg IV once every two weeks on days 1 and 15 of every cycle (cycle defined as 28 days). If the tumor volume remains \< 40 cc, the patient will undergo stereotactic radiotherapy with IMRT (30Gy) beginning anywhere from day 7-10 of cycle 2 (5 doses of 6 Gy over 2 and a half weeks)

Trial Locations (2)

10065

Memorial Sloan Kettering Cancer Center, New York

11725

Memorial Sloan-Kettering Cancer Center @ Suffolk, Commack

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Weill Medical College of Cornell University

OTHER

collaborator

Genentech, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00595322 - Bevacizumab in the Radiation Treatment of Recurrent Malignant Glioma | Biotech Hunter | Biotech Hunter